Literature DB >> 3923948

Photodynamic action of uroporphyrin on the complement system in porphyria cutanea tarda.

M Meurer, C Schulte, A Weiler, G Goerz.   

Abstract

We investigated the effect of UV light (320-460 nm) on total hemolytic CH50 activity and C3 cleavage in sera obtained from 14 patients with porphyria cutanea tarda. Irradiation with 5, 10, or 50 J/cm2 resulted in a 12%-60% loss of CH50 and a 5%-30% cleavage of native C3 as estimated by planimetric evaluation of the immunoelectrophoretic C3 pattern. The complement changes were most pronounced in sera from patients with active disease and were minimal or absent in patients who were in remission. In all cases, the decrease of CH50 and C3 cleavage was proportional to the plasma-porphyrin concentration and the dose of radiation. After exposure to 320- to 460-nm light, similar changes were seen in normal human serum (NHS) to which exogenous uroporphyrin had been added. Beta-carotene and chloroquine had no inhibitory effect on the photodynamic complement activation. The C3 cleavage in irradiated NHS containing uroporphyrin was not affected by 10 mM EGTA, but was partially inhibited in the presence of 30 mM EDTA, thus indicating that the interaction of photoexcited uroporphyrin with the complement system differs from classical-pathway complement activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3923948     DOI: 10.1007/bf00509083

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  16 in total

1.  STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. I. INHIBITION BY TRISODIUM ETHYLENEDIAMINETETRAACETATE (EDTA).

Authors:  M M FRANK; H J RAPP; T BORSOS
Journal:  J Immunol       Date:  1964-09       Impact factor: 5.422

2.  Cutaneous changes in the porphyrias. A microscopic study.

Authors:  J H Epstein; D L Tuffanelli; W L Epstein
Journal:  Arch Dermatol       Date:  1973-05

3.  [Diagnosis of porphyria].

Authors:  M Doss
Journal:  Med Welt       Date:  1977-03-11

4.  A new apparatus with high radiation energy between 320-460 nm: physical description and dermatological applications.

Authors:  M F Mutzhas; E Hölzle; C Hofmann; G Plewig
Journal:  J Invest Dermatol       Date:  1981-01       Impact factor: 8.551

5.  Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda.

Authors:  H W Lim; H D Perez; M Poh-Fitzpatrick; I M Goldstein; I Gigli
Journal:  N Engl J Med       Date:  1981-01-22       Impact factor: 91.245

6.  Erythropoietic protoporphyria. Photoactivation of the complement system.

Authors:  I Gigli; A A Schothorst; N A Soter; M A Pathak
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

7.  Prosser White Oration 1978. The complement system in inflammation and host defence.

Authors:  I Gigli
Journal:  Clin Exp Dermatol       Date:  1979-09       Impact factor: 3.470

8.  Histopathology of the skin in acquired and hereditary porphyria cutanea tarda.

Authors:  R H Cormane; E Szabò; T T Hoo
Journal:  Br J Dermatol       Date:  1971-12       Impact factor: 9.302

9.  Influence of chloroquine on the porphyrin metabolism.

Authors:  G Goerz; K Bolsen; H Merk
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

10.  Role of complement in porphyrin-induced photosensitivity.

Authors:  H W Lim; I Gigli
Journal:  J Invest Dermatol       Date:  1981-01       Impact factor: 8.551

View more
  2 in total

1.  Systemic inflammation in acute intermittent porphyria: a case-control study.

Authors:  E Storjord; J A Dahl; A Landsem; H Fure; J K Ludviksen; S Goldbeck-Wood; B O Karlsen; K S Berg; T E Mollnes; E W Nielsen; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2016-12-15       Impact factor: 4.330

2.  Feasibility of cellular bioenergetics as a biomarker in porphyria patients.

Authors:  Balu Chacko; Matilda Lillian Culp; Joseph Bloomer; John Phillips; Yong-Fang Kuo; Victor Darley-Usmar; Ashwani K Singal
Journal:  Mol Genet Metab Rep       Date:  2019-01-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.